CAR T Cell Therapy Manufacturing: Delivering on the Promise of a Transformational Therapy

Greg Russotti has established himself as a world leader in the field of cell therapy technical development and manufacturing. He joined Celgene over 12 years ago, just as Celgene began major efforts in the cell therapy field.  He was initially responsible for process and analytical development of all cell-based processes at Celgene and was soon appointed CMC lead for Celgene’s placental cell therapy product, PDA-001, with accountability for all technical operations activities, including process and analytical development, clinical production, quality control, quality assurance, and supply chain. Greg later took on functional responsibility for the aforementioned areas for all cell and tissue-based products.